Immunic, Inc. (FRA:10VA)

Germany flag Germany · Delayed Price · Currency is EUR
0.574
+0.006 (1.06%)
At close: Dec 4, 2025
-51.23%
Market Cap 68.72M
Revenue (ttm) n/a
Net Income (ttm) -87.83M
Shares Out n/a
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,089
Average Volume 7,752
Open 0.545
Previous Close 0.568
Day's Range 0.545 - 0.574
52-Week Range 0.519 - 1.363
Beta n/a
RSI 43.70
Earnings Date Feb 26, 2026

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patien... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 91
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 10VA
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.